Unknown

Dataset Information

0

PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.

ABSTRACT: We report the preclinical evaluation of PF-06463922, a potent and brain-penetrant ALK/ROS1 inhibitor. Compared with other clinically available ALK inhibitors, PF-06463922 displayed superior potency against all known clinically acquired ALK mutations, including the highly resistant G1202R mutant. Furthermore, PF-06463922 treatment led to regression of EML4-ALK-driven brain metastases, leading to prolonged mouse survival, in a superior manner. Finally, PF-06463922 demonstrated high selectivity and safety margins in a variety of preclinical studies. These results suggest that PF-06463922 will be highly effective for the treatment of patients with ALK-driven lung cancers, including those who relapsed on clinically available ALK inhibitors because of secondary ALK kinase domain mutations and/or brain metastases.

SUBMITTER: Zou HY 

PROVIDER: S-EPMC4504786 | biostudies-literature | 2015 Jul

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

We report the preclinical evaluation of PF-06463922, a potent and brain-penetrant ALK/ROS1 inhibitor. Compared with other clinically available ALK inhibitors, PF-06463922 displayed superior potency against all known clinically acquired ALK mutations, including the highly resistant G1202R mutant. Furthermore, PF-06463922 treatment led to regression of EML4-ALK-driven brain metastases, leading to prolonged mouse survival, in a superior manner. Finally, PF-06463922 demonstrated high selectivity and  ...[more]

Similar Datasets

Unknown The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.
| S-EPMC4707106 | biostudies-literature
Unknown PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.
| S-EPMC4371934 | biostudies-literature
Unknown A new ALK inhibitor overcomes resistance to first- and second-generation inhibitors in NSCLC
| S-SCDT-EMM-2021-14296 | biostudies-other
Unknown A new ALK inhibitor overcomes resistance to first- and second-generation inhibitors in NSCLC.
| S-EPMC8749467 | biostudies-literature
Unknown The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.
| S-EPMC6688997 | biostudies-literature
Unknown The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN.
| S-EPMC5047689 | biostudies-literature
Unknown Iruplinalkib (WX‑0593), a novel ALK/ROS1 inhibitor, overcomes crizotinib resistance in preclinical models for non-small cell lung cancer.
| S-EPMC10140010 | biostudies-literature
Unknown NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.
| S-EPMC4467397 | biostudies-literature
Unknown Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib.
| S-EPMC5700232 | biostudies-literature
Unknown Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.
| S-EPMC5050111 | biostudies-literature